International Brain Health Conference 2026 highlights

The first International Brain Health Conference took place in Edinburgh on 18-19 May 2026. With a theme of Advancing Brain Health, IBHC2026 brought together international leaders to explore the latest advances in understanding brain health and its role in preventing neurodegenerative disease.

200 attendees from the life sciences and pharmaceutical industry, academia, policy and healthcare industry attended to listen to presentations, network and learn about developments from sponsors and partners.

Man standing on a stage in front of a lecturn
Man standing on a stage in front of a lecturn

Through the lenses of public health, personalised medicine, and early detection, the conference examined emerging tools, biomarkers, and service models that enable earlier, more effective intervention and support brain health across the life course.

Watch the highlights video to get a flavour of the International Brain Health Conference 2026.

More news

© VadimGuzhva Adobe Stock

The silent victims of brain injury

In recent years more and more evidence has been found of the link between head injuries – be it at work, at war or on the sports field – and the onset of neurological conditions several or many years later. A neuropathologist involved in leading research at the University of Glasgow says the message to those affected is that you can take steps, and you shouldn’t give up hope. However, Professor Willie Stewart also says he believes that there is one group of people at risk are remaining silent.
Read more
Scottish Brain Services News

Pharma companies collaborate on early Alzheimer’s diagnoses

Roche has announced its collaboration with its counterpart Eli Lilly to try to achieve early diagnosis of Alzheimer’s disease using the diagnostic Elecsys Amyloid Plasma Panel – testing blood plasma for key Alzheimer’s disease markers.
Read more
Dr John Harrison

Redefining clinical meaningfulness

A World Dementia Council Summit will this week (Monday) discuss how teams conducting clinical research into Alzheimer’s disease and wider dementia can measure what matters when some interventions clearly benefit patients but may not deliver the dramatic improvements needed to meet current definitions of effectiveness.
Read more
Scottish Brain Sciences Biomarker Laboratory Achieves ISO 15189 Accreditati...Alzheimer’s blood and biomarker testing service launched to support earlier...